Nanobiotix Labege (NNBXF) Financials
Newest figures come from the filing for FY2025, filed Mar 31, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the NNBXF SEC filings page.
Nanobiotix Labege (NNBXF) reported $38.3M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Financial Health Signals
We do not publish a peer-relative financial health score for Nanobiotix Labege, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Nanobiotix Labege passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Nanobiotix Labege reported a net loss of $28.1M while operations used $39.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Nanobiotix Labege reported an operating loss of $12.7M against $17.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Nanobiotix Labege generated $38.3M in revenue in fiscal year 2025.
Nanobiotix Labege's EBITDA was -$10.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
Nanobiotix Labege reported a net loss of $28.1M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Nanobiotix Labege earned -$0.59 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
Nanobiotix Labege recorded an outflow of $39.9M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Nanobiotix Labege held $61.9M in cash as of fiscal year 2025; no long-term debt figure is on record for that period.
Not reported for fiscal year 2025.
Margins & Returns
Nanobiotix Labege's operating margin was -33.2% in fiscal year 2025, reflecting core business profitability.
Nanobiotix Labege's net profit margin was -73.5% in fiscal year 2025, showing the share of revenue converted to profit.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Nanobiotix Labege invested $27.1M in research and development in fiscal year 2025. This represents a decrease of 35.4% from the prior year.
Nanobiotix Labege invested $631K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 27.9% from the prior year.
Not reported for fiscal year 2025.
NNBXF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.3M | N/A | $40.1M+683.9% | $5.1M+70.5% | $3.0M-2.5% | $3.1M+7.7% | $2.9M-28.4% | $4.0M |
| R&D Expenses | $27.1M-35.4% | $42.0M-1.2% | $42.5M+21.7% | $34.9M+1.5% | $34.4M+15.5% | $29.8M-12.8% | $34.1M+42.6% | $23.9M |
| Operating Income | -$12.7Mn/m | -$70.8Mn/m | -$29.6Mn/m | -$50.0Mn/m | -$59.5Mn/m | -$44.6Mn/m | -$52.5Mn/m | -$34.4M |
| EBITDA | -$10.9Mn/m | -$69.1Mn/m | -$27.9Mn/m | -$48.4Mn/m | -$57.7Mn/m | -$42.4Mn/m | -$50.5Mn/m | -$33.7M |
| Interest Expense | $17.9M+130.7% | $7.8M-52.7% | $16.4M+10.4% | $14.8M+1579.9% | $883Kn/m | -$5.7M-214.9% | $5.0M+413.0% | $970K |
| Income Tax | $4K-96.6% | $105K-21.2% | $133K+1140.8% | $11K+89.0% | $6K-48.6% | $11K+226.8% | $3Kn/m | $0 |
| Net Income | -$28.1Mn/m | -$70.5Mn/m | -$43.9Mn/m | -$61.0Mn/m | -$53.3Mn/m | -$41.1Mn/m | -$57.2Mn/m | -$34.8M |
| EPS (Basic) | -$0.59n/m | -$1.49n/m | -$1.19n/m | -$1.75n/m | -$1.53n/m | -$1.69n/m | -$2.64n/m | -$1.78 |
| EPS (Diluted) | -$0.59n/m | -$1.49n/m | -$1.19n/m | -$1.75n/m | -$1.53n/m | -$1.69n/m | -$2.64n/m | -$1.78 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, Diluted Shares (Avg).
NNBXF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $79.5M+14.0% | $69.8M-32.8% | $103.9M+62.4% | $63.9M-44.5% | $115.2M-29.7% | $163.9M+159.8% | $63.1M+6.8% | $59.1M |
| Current Assets | $73.6M+15.7% | $63.6M-34.1% | $96.6M+72.5% | $56.0M-46.8% | $105.3M-31.2% | $153.2M+195.8% | $51.8M+6.3% | $48.7M |
| Cash & Equivalents | $61.9M+20.2% | $51.5M-38.2% | $83.3M+88.1% | $44.3M-53.4% | $95.0M-34.8% | $145.7M+269.9% | $39.4M-5.0% | $41.5M |
| Total Liabilities | $178.7M+29.7% | $137.8M+30.1% | $105.9M+14.0% | $92.9M+9.4% | $84.9M+9.2% | $77.7M+19.1% | $65.2M+52.5% | $42.8M |
| Current Liabilities | $67.5M+10.6% | $61.0M+10.6% | $55.2M+35.9% | $40.6M-2.7% | $41.7M+79.1% | $23.3M+44.6% | $16.1M+15.7% | $13.9M |
| Non-Current Liabilities | $111.2M+44.8% | $76.8M+51.4% | $50.7M-3.0% | $52.3M+21.2% | $43.2M-20.7% | $54.5M+10.8% | $49.1M+70.3% | $28.9M |
| Total Equity | -$99.1Mn/m | -$68.0Mn/m | -$2.0Mn/m | -$28.9M-195.4% | $30.3M-64.8% | $86.2Mn/m | -$2.1M-113.1% | $16.3M |
| Retained Earnings | -$470.4Mn/m | -$393.8Mn/m | -$306.2Mn/m | -$243.1Mn/m | -$207.6M | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
NNBXF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$39.2Mn/m | -$20.2Mn/m | -$13.8Mn/m | -$39.7Mn/m | -$33.8Mn/m | -$33.7Mn/m | -$46.2Mn/m | -$29.8M |
| Depreciation & Amortization | $1.8M+4.6% | $1.7M+0.3% | $1.7M+4.3% | $1.6M-9.1% | $1.8M-17.7% | $2.1M+8.1% | $2.0M+179.8% | $709K |
| Capital Expenditures | $631K-27.9% | $876K+141.3% | $363K+268.7% | $98K-61.9% | $258K+119.8% | $117K-90.4% | $1.2M+157.0% | $477K |
| Free Cash Flow | -$39.9Mn/m | -$21.1Mn/m | -$14.2Mn/m | -$39.8Mn/m | -$34.1Mn/m | -$33.8Mn/m | -$47.4Mn/m | -$30.2M |
| Investing Cash Flow | -$678Kn/m | -$989Kn/m | -$386K-361.5% | $148Kn/m | -$274Kn/m | -$137Kn/m | -$1.6M-2113.9% | $81K |
| Financing Cash Flow | $43.9Mn/m | -$5.3M-110.3% | $51.7Mn/m | -$6.0Mn/m | -$5.9M-104.3% | $136.7M+193.5% | $46.6M+173.8% | $17.0M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
NNBXF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY25Filing | FY24Filing | FY23Filing | FY22Filing | FY21Filing | FY20Filing | FY19Filing | FY18Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -33.2% | N/A | -74.0% | -977.8% | -1986.4% | -1450.2% | -1841.0% | -864.2% |
| Net Margin | -73.5% | N/A | -109.7% | -1194.3% | -1778.0% | -1337.2% | -2003.7% | -872.2% |
| Return on Equity | N/A | N/A | N/A | N/A | -175.7%-128.0pp | -47.7% | N/A | -213.1% |
| Return on Assets | -35.4%+65.7pp | -101.1%-58.8pp | -42.3%+53.2pp | -95.4%-49.2pp | -46.2%-21.2pp | -25.1%+65.5pp | -90.6%-31.8pp | -58.8% |
| Current Ratio | 1.090.0x | 1.04-0.7x | 1.75+0.4x | 1.38-1.1x | 2.53-4.1x | 6.58+3.4x | 3.22-0.3x | 3.50 |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | 2.80+1.9x | 0.90 | N/A | 2.62 |
| Asset Turnover | 0.48+0.6x | -0.11-0.5x | 0.39+0.3x | 0.08+0.1x | 0.030.0x | 0.020.0x | 0.050.0x | 0.07 |
| FCF Margin | -104.2% | N/A | -35.4% | -778.8% | -1137.1% | -1100.1% | -1663.1% | -758.9% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$99.1M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Where Nanobiotix Labege Ranks
Frequently Asked Questions
Nanobiotix Labege (NNBXF) reported $38.3M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
No, Nanobiotix Labege (NNBXF) reported a net loss of $28.1M in fiscal year 2025, with a net profit margin of -73.5%.
Nanobiotix Labege (NNBXF) had EBITDA of -$10.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Nanobiotix Labege (NNBXF) had an operating margin of -33.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
Nanobiotix Labege (NNBXF) had a net profit margin of -73.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Nanobiotix Labege (NNBXF) recorded an outflow of $39.9M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Nanobiotix Labege (NNBXF) recorded an outflow of $39.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Nanobiotix Labege (NNBXF) had $79.5M in total assets as of fiscal year 2025, including both current and long-term assets.
Nanobiotix Labege (NNBXF) invested $631K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Nanobiotix Labege (NNBXF) invested $27.1M in research and development during fiscal year 2025.
Nanobiotix Labege (NNBXF) had a current ratio of 1.09 as of fiscal year 2025, which is considered adequate.
Nanobiotix Labege (NNBXF) had a return on assets of -35.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Nanobiotix Labege (NNBXF) has negative shareholder equity of -$99.1M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
Nanobiotix Labege (NNBXF) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Nanobiotix Labege (NNBXF) reported a net loss of $28.1M while operations used $39.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Nanobiotix Labege (NNBXF) reported an operating loss of $12.7M against $17.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.